Corvus Pharmaceuticals/$CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Ticker
$CRVS
Sector
Primary listing
Employees
37
Headquarters
Website
CRVS Metrics
BasicAdvanced
$1bn
-
-$0.55
0.94
-
Price and volume
Market cap
$1bn
Beta
0.94
52-week high
$26.95
52-week low
$3.55
Average daily volume
1.7m
Financial strength
Current ratio
19.814
Quick ratio
19.646
Long term debt to equity
0.169
Total debt to equity
0.347
Profitability
EBITDA (TTM)
-47.814
Management effectiveness
Return on assets (TTM)
-19.16%
Return on equity (TTM)
-30.46%
Valuation
Price to book
4.16
Price to tangible book (TTM)
4.16
Price to free cash flow (TTM)
-28.28
Free cash flow yield (TTM)
-3.54%
Free cash flow per share (TTM)
-0.421
Growth
Earnings per share change (TTM)
-44.46%
3-year earnings per share growth (CAGR)
-14.47%
10-year earnings per share growth (CAGR)
-37.47%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs